基于《内经》肝“生血气”理论探讨调肝生血法对骨髓抑制小鼠外周血清IL-6、IL-11、TPO的影响
详细信息    本馆镜像全文|  推荐本文 |  |   获取CNKI官网全文
摘要
目的:基于《黄帝内经》肝“生血气”理论,研究从肝论治放、化疗后骨髓抑制的作用机制,为临床治疗放、化疗后骨髓抑制提供新的思路和方法,也为进一步研究中医肝藏血理论提供理论和实验依据。
     方法:用60Co-γ射线一次性照射昆明小鼠制作骨髓抑制模型,观察根据调肝生血法组方的中药(简称柴胡生血方)对小鼠外周血血象及外周血血清白细胞介素6、白细胞介素11、促血小板生成素含量的影响。
     结果:实验研究发现:调肝生血法能增加骨髓抑制后小鼠外周血白细胞、红细胞、血小板数量,增加血小板分布宽度、平均血小板体积;调肝生血法能促进外周血血清中白细胞介素6、白细胞介素11、促血小板生成素表达的作用。
     结论:调肝生血法可能通过促进外周血血清中促进白细胞介素6、白细胞介素11、血小板生成素表达的作用,从而促进造血干细胞的增殖和分化,进一步促进骨髓增殖,提高外周血血小板、中性粒细胞、红细胞等的水平。表明《内经》肝“生血气”等理论有临床指导意义。
Objective:Based on the "Inner Canon of Yellow Emperor" liver " Metaplasia blood and qi " theory, research, and chemotherapy treatment from liver put after the mechanism of action of inhibit bone marrow, for clinical treatment after chemotherapy inhibit bone marrow put, provide new train of thought and method, also for further study traditional Chinese medicine liver storing blood theory provide theoretical and experimental basis.
     Methods:With60Co-γ rays kunming mice one-time illuminate making bone marrow inhibition models, observe the adjustable liver raw blood method according to the formula Chinese medicine (hereinafter referred to as the chaihu shengxuefang) party adopted in mice and peripheral blood serum and peripheral blood platelet erythropoietin, interleukin11, the influence of interleukin6content.
     Results:Experimental study found that:Adjustable liver raw blood method can increase blood liver raw bone marrow inhibit mice, the peripheral blood red blood cells, platelets leukocyte, population, increase platelet distribution width, average platelet volume; The method can promote blood liver was born in peripheral blood serum erythropoietin, promote platelet interleukin11interleukin6, the role of expression.
     Conclusions:Adjustable liver raw blood method can in serum erythropoietin, promote platelet interleukin11interleukin6, the role of expression, so as to promote the hematopoietic stem cell proliferation and differentiation, further promote bone marrow proliferation, improve the peripheral platelets and white blood cells, the level of red blood cells, etc. Show that the theory of liver " Metaplasia blood and qi' theory have clinical significance.
引文
[1]吴秋霞,徐振晔.中药治疗骨髓抑制的实验研究进展[J].浙江中医杂志,2005,45(8):618-621.
    [2]张苗海、张英羽.中医药防治化疗后血.小板减少症的研究进展[J].现代中西医结合杂志.2009,18(23):2868-2870.
    [3]陈钢,徐薇,王良,等,小柴胡汤与四物汤合煎改善血虚小鼠造血机能的实验研究.辽宁中医杂志[J].2010,37(2):232-233.
    [4]杨天楹.关于骨髓造血功能衰竭[J].中国危重病急救医学,1996,8(1):34-35
    [5]邓家栋,杨崇礼,杨天楹等.邓家栋临床血液学[M].上海:上海科学技术出版社,2001:1576-1584.
    [6]陈季强,唐法娣.药源性疾病:基础与临床[M].北京:人民卫生出版社,1997,343-374.
    [7]陈荣.药物对造血系统的研究进展[J].中国医药指南,2010,10,8(30)
    [8]温新宇,王玲,田亚平.四生汤对辐射损伤小鼠的保护作用[J].军医进修学院学报.2011,31(9):921-923.
    [9]陈家佩,毛秉智.辐射血液学:基础与临床[M].1版.北京军事医学科学出版社,2002:115-117.
    [10]Chklovskaia E, jansen W, Nissen C, et al. Mechanism of flt3 ligand experession in bone narrow failure; translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis[J]. Blood,1999,93(8):2595-2604.
    [11]都丽萍,梅丹.药源性血小板减少症的发病机制和临床表现及防治[J].药物不良反应杂志,2007,9(6):414-419.
    [12]李德冠,孟爱民.造血干细胞衰老机制研究[J].中国药理学通报.2008,24(6):701-704.
    [13]刘剑毅,黄崇刚,罗先钦,等.60Co照射制备小鼠白细胞减少症模型研究[J].中药药理与临床,2008,24(4):65-68.
    [14]冯全生,刘继林,黄国均,等.补肝肾益气血方对60Co射线所致小鼠骨髓造血.细胞损伤的影响[J].成都中医药大学学报,2003,26(4):30-32.
    [15]滕增辉,田琼,梅其炳等rhBMP-2m对辐射小鼠骨髓CD34+细胞变化的影响[J].中国药理学通报,2004,20(6):619-722.
    [16]沈云辉,陈长勋.双黄升白颗粒剂对白细胞减少症模型小鼠造血.细胞作用的研究[J].中国中药杂志,2006,31(9):754-759.
    [17]李欣娜,李魏.骨髓抑制动物模型建立方法综述[J].黑龙江医药,2008,21(2):24-27.
    [18]孙汭,田志刚.叠氮胸昔诱导小鼠骨髓抑制模型的建立[J].中华传染病杂志,2001,6(19):166-168.
    [19]唐小江,王致,李南春等.苯致白细胞减少大鼠模型的复制[J].中国职业医学,2006,6(33):180-182.
    [20]彭亦良.造血干细胞调控因子研究进展[J].中国误诊学杂志,2001,1(10):1476-1477.
    [21]孙凯,金伯泉,朱勇,等.白细胞介素-11对小鼠骨髓造血的影响[J].单克隆抗体通讯,11(1):31-35.
    [22]孙凯.白细胞介素11基因治疗促进造血的实验研究[J].中国免疫医学杂志,1997,13(2):71-75.
    [23]杨岚.白细胞介素6与造血.调控[J].国外医学输血及血液学分册,1995,18(1):40-43.
    [24]DeBruvn C, Delforge A, Martiat P, et al. Exvivo expansion of megakaryocyte progenitor cells:cord blood versus mobilized enpheral blood[J]. Stem Cells Dev,2005,14(4):415-424.
    [25]陈淑萍,陈慧菁,叶韵斌,等.TPO、PDGF、IL-11在脐血巨核细胞生长和分化中的作用[J].福建医科大学学报.2006,40(4):330-333.
    [26]田卫卫,王庆苗.恶性肿瘤化疗后骨髓抑制的病机及临床治疗探讨[J].河北中医,2000,22(10):791-792.
    [27]王保健,王建红,王建峰.血的化生肾阳为本[J].中国城乡企业卫生,2006,(6):72-74.
    [28]陈昌华,石林阶,陈国林,等.肝血虚证患者36例的血液流变学测定[J].湖南中医杂志,1996,12(1):38-41.
    [29]唐晓勇,孙振高.再生障碍性贫血从肝论治探微[J].中医杂志.2003,44(3):165-166.
    [30]徐希岳,王启之,吴炎,等.肝硬化患者骨髓特征的临床观察.临床荟萃.2000.15(4):153.
    [31]皇甫谧.针灸甲乙经[M].北京:人民卫生出版社,2006:36.
    [32]孙广仁.中医基础理论[M].北京:中国中医药出版社,2006:106.
    [33]黄帝内经·灵枢[M].四川科学技术出版社,2008:112.
    [34]陆鹏.少阳主骨浅析[J].甘肃中医,2009,22(9):7-8.
    [35]王鸿度,张丰正,游慧,等.“少阳主骨”理论考辨[J].中国针灸,2008,28(6):2.
    [36]张喜芬,梅晓云.肝肾同源论[J].辽宁中医学院学报,2005,7(6):578.
    [37]施维.肝肾同源刍议[J].陕西中医,2006,27(5):575-577.
    [38]王玉芳.浅谈肝之疏泄在五脏中的作用[J].中医药信息,2010,27(3):10-11.
    [39]陈邦芝.从肝论治男子性功能障碍举隅[J].四川中医,1996,14(1):32-33.
    [40]田应昌,邹筑良.试论肝硬化的治疗思路[J].贵阳中医学院学报,1999,21(3):7.
    [41]诸晓英.“肝肾同源”理论在针灸临床中的运用[J].中国针灸,1998,(7):415-416.
    [42]何健.治疗消渴勿忘疏肝[J].实用医技杂志,1998,5(5):334.
    [43]蔡定芳,沈自尹,张玲娟,等.命门合剂对大鼠神经内分泌网络的影响[J].中国中西医结合杂志,1995.15(3):159.
    [44]叶蕾.试论肝生血气与肝藏血.[J].江苏中医药,2005,26(2):44-45.
    [45]魏伟.血液化生与肝肾关系及临证应用辨析[J].中医药学刊,2001,(19):112-113.
    [46]江磊磊,张传永.试论治血先治肝[J].新中医,2009,41(4):107-108.
    [47]朱雅琪,朱权,金振锋.消化内科主治医生400问[M].北京:中国协和医科大学出版社.2001:253.
    [48]李德新.气血.论[M].沈阳:辽宁科学技术出版社1990.105.
    [49]张安玲,赵为爱.肝气郁结的证候特点与制方规律[J].山东中医药大学学报,1997,21(3):180-181.
    [50]叶惠燕.“肝生血气”蠡测[J].黑龙江中医药,1984,(2):23-24.
    [51]周华云,周剑影,王国权,等.白细胞介素-6及肿瘤坏死因子对受照小鼠造血恢复的影响[J].辐射防护,2001,21(4):232-236.
    [52]汤伟,徐芳芹,赵华等.病毒性肝炎肝动脉血流变化及其临床意义.南通医学院学报,1997;17(2):179-180.
    [53]丛培玮,许南阳.浅析“凡十一脏取决于胆”[J].辽宁中医药大学学报,2008,10(5):66-67.
    [54]曹丽萍,骨髓抑制患者血小板参数变化探索分析[J].齐齐哈尔医学院学报.201031(9):1428-1429.
    [55]周敏,杨默.血小板生成素相关分子研究进展[J].实用儿科临床杂志.2009,24(15):1141-1144
    [56]Kirshenbaum AS, Akin C, Goff JP, et al. Thrombopoietin alone or in the presence of stem cell factor supports the growth of KITCD117/MPLCD110+human mast cells from hematopoietic progenitor cells[J].Exp Hematol,2005:33 (4):413.
    [57]Chen w,Antonenko S, Sederstrom J M, et al. Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors [J].Blood,2004:103(7):2547.
    [58]BorotaR. Clinicaluse of thrombopoietin (c-Mpl Ligand) [J].Med Pregl 1998,51 (11-12):501-508.
    [59]Fujiwara T, Harigae H, Kameoka J, et al. A case of familial thrombosytosis possible role of altered thrombopoietin production[J]. Am J Hematol,2004; 76 395-397.
    [60]Seita J, Ema H, OoeharaJ, et al. Lnk negatively regulates self-renewal of hem at opoietic stem cells bymodifying thrombopoietin-mediated signa transduction [J].Proc Natl Acad Sc USA,2007,104:2349-2354
    [61]Folman CC, et al. Platelets release thrombopoietin(TPO)upon activation:another regulatory loop in thrombocytopoiesis[J]. Thromb Haemost,200,83 (6):923.
    [62]杨默.提升血小板药物的研究[J].中国处方药.2004,3l(10):25-30.
    [63]杨玲,辜学忠,佟力,等.血小板减少症患者血清促血小板生成素的检测[J].昆明医学院学报,2005,(1):38-41.
    [64]李恩庆,赵安斌,曹克俭.六味地黄汤、补中益气汤、复方丹参饮对骨髓抑制小鼠保护的作用机制[J],中国实验方剂学杂志,2010,16(5):153-156.
    [65]杨玲,申政磊,尹列芬,等.P27在急性自血病患者中表达的研究[J].临床血液病杂志,2004,17(6):331-333.
    [66]吕秋军,高月.白介素11抗辐射损伤作用的研究进展[J].中华放射医学与防护杂志,2000,20(5):369-370.
    [1]Herodin F, Dronet M. Cytokine-based treatment of accidentally irradiated victims and new approaches[J].Exp Hematol,2005,33, (10):1071-1080.
    [2]项文,马增春,潭洪铃等.四物汤及其各组份对射线诱发血虚证小鼠的补血作用[J].中华临床医药与护理,2005,30(12):1.
    [3]克晓燕,孟志云,窦桂芳.粒细胞集落刺激因子的研究新进展[J].中国实验血液学杂志,2008,16(2):452-456.
    [4]卞咏梅,刘金宏.rhG-CSF, rhGM-CSF在血液病治疗中的应用[J].医学综述,1999,5(3):119-121.
    [5]易湛苗,张照辉,翟所迪等.辐射防护与辐射治疗剂临床应用及进展[J].药学进展.2009,6(4):239-242.
    [6]祝东友,孔锐.补肾升自汤配合穴位注射治疗恶性肿瘤放化疗后白细胞减少症36例[J].陕西中医,2003,24(12):1062.
    [7]de Sauvage FJ, Hass PE, Spencer SD, et al, Stinulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand [J]. Nature,1994; 369 533-538.
    [8]Lok S Kaushansky K, Holy RD, et al. C loning and expression of murine thromnbopoietin cDNA and stimulation of platelet production in vivo[J]. Nature,1994 369 565-568.
    [9]Bartley TD, BogenbergerJ, Hunt P, et al. Identification and cloning of amegakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl[J]. cell,1994,77:1117-1124.
    [10]Sohm a Y, Akahori H, Seki N, et al. Molecular cloning and chromosom al localization of the human throbopietin gene[J].FEBS Lett,1004,353:57-61.
    [11]王可洲,杨娟娟,舒心.几种细胞因子与辐射损伤防治的关系研究进展[J].中国辐射卫生.2005,14(2):149-150.
    [12]Cohen-Sol al K, Villeval JL, Tieux M, et al. Constitutive expression of mpl 1 ligand transcripts during thrombocytopenia or thrombocytosis[J]. Blood,1996,88(7): 2578-2584.
    [13]Kaushansky K, Lin N, Chossmann A, et al. Thrombopoietin expands erthroid, granulocyte macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice[J]. Exp Hematol,1996,24(2):265-269.
    [14]Neelis KJ, DubbeLman YD, Qingliang L, et al. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhsus monkeys prevents thrombocytopenia, accelerate splatlet and red cell reconstitution,alleviates neutropenis, and promotes the recovery of immature bone marrow cells[J].Exp Hematol,1997,25(10):1084-1093.
    [15]Neelis KJ, Visser TP, Dimjati W, et al, A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopu-lating cells[J]. blood,1998,92(5):1586-1597.
    [16]姚伟荣,万会平,孟晓晖.重组人血小板生成素对化疗后骨髓抑制的疗效观察[J].实用癌症杂志,2009,24(6):637-638.
    [17]Du X, William s DA. interleuk in-11:review of molecular, cell biology.and clinical use[J]. Blood,1997; 89(11):3897-908
    [18]Saitoh M, Taguchi K, Momose K, et al. Recombinant human interleukin-11, improved carboplatin-induced thrombocy-topenia without affecting antitumor activities in mice bearing Lewis lung careinoma cells [J]. Cancer Chemother Pharmacol,2001, 49:161-166.
    [19]Saitoh M, Taguchi K, Momose K, et al. Kinetic analyis of megakaryopoiesis induce by recombinant human interleukin-11 in myelosuppressed mice[J]. Cytokine,2001, 13:287-294.
    [20]Tsim beridou AM, Giles FJ,Khouril,et al. Low-dose interleukin-11 patients with bonem arrow failue update of the M.D.Anderson Cancer center experience[J]. ann Oncol,2005;16(1):139-45.
    [21]刘鹏辉,曲怡梅,廖国清等.重组人白介素-11治疗化疗后血小板减少症[J].中国老年学杂志,2010,30(10):2756-2757.
    [22]王秀美,吕静等.重组人白细胞介素-11防治化疗所致血小板减少[J].国外医学肿瘤学分册,2003,30(6):439-440.
    [23]张传勇.血小板减少症治疗的研究进展[J].黑龙江医药,2008,21(3):20-21.
    [24]卢学春,朱宏丽,迟小华.氨磷汀作用的研究进展[J].中国药物应用与监洲,2008.5(1):48-51.
    [25]Cassatt DR, Fazenhaker CA, Bachy CM, et rall. Preclinical modeling of improved amifostine (ethyol) use in radiation therapy [J]. Semmars in Radiation Oncology, 2002,12(1):97-102.
    [26]Sarna L, Swarm S, Langer C, et al. (ainically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung canacr:an analysis of RTOG 9801[J]. Int J Raidat Oncol Biol Phys 2008,72(5):1-7.
    [27]Jeffrey MC. Current issues with platelet transfusion in patient with cancer. seminars in Hematology.2000.37(suppl4):3-10.
    [28]张爱军,侯明.血浆置换在血小板减少症中的应用[J].血栓与止血学,2005,11(4):183-185.
    [29]马海珍,侯相麟,刘蓓,等.血浆置换及血.细胞单采的临床疗效观察[J].临床血液学杂志,2004,17(5):292-293.
    [30]李戈.骨髓抑制防治概况[J].中医药学刊,2006,24(5):888-889.
    [31]裴传宝,王羲明,王蜊琳,等.中药扶正联合化疗治疗晚期非小细胞肺癌[J].辽宁中医杂志,2003,30(4):266-267.
    [32]李茂玲.血小板减少性紫癜辨证论治体会[J].云南中医中药杂志,2010,31(10):33.
    [33]邹鑫.益血宁治疗血小板减少性紫瘢临床辨析[J].河南中医学院学报,2005,20(2):39-40.
    [34]何成云.辨证治疗血小板减少性紫瘫36例[J].中医杂志,2010,51:175-176.
    [35]张宽智,林建民,杨英军,等.辨证治疗癌症化、放疗毒副反应[J].中医肿瘤临床与康复,2001,8(5):78-80.
    [36]王玉华,曲士杰,郭郁,等.扶正培本法防治肿瘤化疗后白细胞血小板减少[J].中国民间疗法,2001,9(11):48.
    [37]张蓓,胡不丽,丘惠娟,等.升板方治疗化疗后血小板减少的疗效观察[J].癌症,2004,23(11):1470-1472.
    [38]姚莉,许高.升板汤治疗肿瘤放化中血小板减少100例[J].黑龙江中医药,2008,(1):14-15.
    [39]汪照清,潘金玲.青紫合剂和胡枣二胶膏治疗血小板减少性紫癜[J].中医药研究,200l,17(3):26.
    [40]脾梁慧,蔡美.脾肾方防治化疗后骨髓抑制64例总结[J].湖南中医杂志,2006,22(3):3-4.
    [41]陈新军.健脾益肾治疗化疗后血小板减少疗效观察[J].现代中西医结合杂志,2007,16(9):1191-1192.
    [42]李海,赵增虎,李成云,等.健脾意气养血中药对化疗患者外周血小板的影响[J].中国中医急症,2006,15(6):599-600.
    [43]刘章玺.健脾升白合剂治疗放疗后白细胞减少60例[J].首都医药,2007, (10):33-34.
    [44]薛育新,杨建平.化疗扶正汤治疗化疗所致骨髓抑制96例临床观察[J].光明中医,2008,23(4):487-488.
    [45]黄利华,古学奎.丘和明教授从肝肾论治血小板减少性紫瘫经验介绍[J].新中医,2010,42(11):127-128.
    [46]姜梅芳,岳麓,吉秀芹.复元汤治疗化疗毒副反应30例临床观察[J].新中医,40(9):38-39.
    [47]付文胜.四君子汤加味治疗化疗后血小板减少40例[J].实用中医药杂志,2005,21(5):270.
    [48]陈声池.益气补血.升板方治疗化疗后血小板减少症28例[J].福建中医学院学报,2009,19(1):11-12.
    [49]朱翔,方明治,黄欣,等.滋阴养血.治疗结直肠癌化疗后血.小板减少临床观察[J].辽宁中医药大学学报,2010,12(2):145-146.
    [50]洪永贵,张玉芳,王俊生,等.益血升板汤治疗化疗致血小板减少疗效观察[J].中国中医药信息杂志,2009,16(12):56-57.
    [51]宋振民,宋会群,陈述.养血胶囊治疗肿瘤放、化疗后白细胞、血小板减少91例临床观察[J].药物与临床,2009,6(22):107-108.
    [52]王春霞,王希胜.龙华胶囊治疗化疗后血小板减少症疗效观察[J].实用中西医结合临床,2010,10(1):44-45.
    [53]文欣轩.地榆升白片治疗晚期肿瘤化疗致血小板减少的临床分析[J].中国中医药信息杂志,2005,12(10):77-78.
    [54]刘人为,谢晓冬,单学健,等.参附注射液对乳腺癌化疗所致骨髓抑制的影响研究[J].中医药学刊,2004,22(8):1483
    [55]彭万军,刘伯学,王春.参麦注射液治疗恶性肿瘤化疗后骨髓抑制临床观察[J].浙江中医学院学报,2001,25(6):24.
    [56]白献红,洪锡田.参麦防治肿瘤化疗所致骨髓抑制[J].医药论坛杂志,200324(15):59-60.
    [57]顾丽梅,吴剑平,史纯璞.复方皂矾丸防治化疗所致血小板减少临床观察[J].临床研究,2009,47(29):34-35.
    [58]宋兴华,司徒红林.中医药治疗化疗后骨髓抑制研究进展[J].浙江中西医结合杂志,2009,19(5):326-328.
    [59]文欣轩.地榆升白片治疗晚期肿瘤化疗致血小板减少的临床分析[J].中国中医药信息 杂志,2005,12(10):77-78.
    [60]马廷行,田静,李春华,等.升柏和味海参口服液防治化疗所致骨髓抑制临床研究[J].实用中医药杂志,2008,24(5):268-269.
    [61]潘迎英,杨怡敏,陶敏贤.维血宁颗粒治疗化疗后血小板减少38例临床观察[J].长春中医药大学学报,2010,26(4):541-542.
    [62]匡霞,郭明广.血康胶囊在急性白血病化疗中的应用[J].河南大学学报(医学版),2009,28(4):298-299.
    [63]徐卫国.血康口服液的临床应用[J].综述报告,2005,14(4):79-80.
    [64]陈天池,文海英,秦志丰,等.养血饮口服液治疗化疗后白细胞与血小板减少32例临床观察[J].时珍国医国药,2007,18(4):976.
    [65]李勇.贞茂扶正颗粒防治乳腺癌化疗不良反应的临床观察[J].中国厂矿医学,2008,21(2):225.
    [66]刘焕义,苏晓妹,魏东.大剂量阿胶治疗恶性肿瘤放疗所致血小板减少的临床观察[J]西南军医,2006,8(2):31-32.
    [67]洪永贵,王洪海,张玉芳.鸡血.藤治疗化疗致血小板减少[J].中医杂志,2003,44(10):730.
    [68]钟立业,刘天浩,陈运贤,等.肿节风防治化疗后血小板减少症的研究[J].中药材,2005,28(1):35-37.
    [69]李丽华,项钟明,陈立宏,等.中西医结合治疗化放疗中血小板减少疗效观察[J].肿瘤防治杂志,2001,8(2):205.
    [70]王羽,王佩,李文燕.中西医结合治疗化疗引起血小板减少62例[J].河南中医学院学报,2007,22(6):133.
    [71]卢介珍,陈鹏,叶勇智,等.中西医结合治疗肿瘤化疗后血小板减少症30例[J].中国中西医结合杂志,2001,21(10):785-786.
    [72]周维顺,谢长生,吴良村.等.中西医结合治疗化疗后缸小扳减少症150例[J].中国中两结合外科杂,1997,3(2):126-127.
    [73]何流,钱志英.中西医结合防治肿瘤化疗所致骨髓抑制的临床研究[J].肿瘤研究与临床,2006,18(3):411-412.
    [74]黄智芬,刘俊波,黄常江等.黄芪注射液配合两药治疗肿瘤化疗后血小扳减少症30例[J].中国中医药科技,2010,17(1):21.
    [75]永丽楠,刘巍.化疗后血小极减少症治疗进展[J].现代肿瘤医学,2007,15(2):281-283.